EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

The TMA team and TTP pathway improved outcomes in a cohort with Thrombotic thrombocytopenic purpura

Samuel A Merrill iD, Stephen Yu, Sylvia E Webber, John Gotses, Emma L Platt, Ruta Arays, Aaron D Shmookler iD

PLOS One · 2025

DOI: 10.1371/journal.pone.0325417 ↗

Kurz gefasst

Fachartikel in der Zeitschrift PLOS One, 2025. Verfasst von Samuel A Merrill und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, West Virginia University School of Medicine, Morgantown, West Virginia, United States of America. Hauptthemen laut MEDLINE: Purpura, Thrombotic Thrombocytopenic, Patient Care Team, Thrombotic Microangiopathies. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 55 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Providing optimal care for patients with thrombotic thrombocytopenic purpura (TTP) is challenging because of multiple involved specialties, knowledge gaps, and a high rate of disease relapse. A thrombotic microangiopathy (TMA) Team and TTP Pathway could improve outcomes.

Objectives

To assess if a structured TTP Pathway, supported by a TMA Team, improved TTP care by reducing TTP relapse and TTP-related death (TTP-RRD) at a rural Appalachian medical center.

Methods

Prospective cohort quality improvement project using the DMAIC quality improvement framework (Define, Measure, Analyze, Improve, Control) to develop a TMA Team and TTP Pathway. Pathway care included standardized use of therapeutic plasma exchange (TPE), rituximab, caplacizumab, as well as improved coordination between medical services, and regular outpatient biochemical TTP surveillance. Outcomes were determined by retrospective chart review for patients with acute TTP treated with usual care (N = 16 episodes) and the TTP Pathway (N = 16 episodes). Results and conclusions All patients had acquired TTP. TTP-RRD at 90 days was reduced from 69% with usual care to 6% with Pathway care (95% CI 0.35 to 0.90, P = 0.0004), a relative risk reduction of 91%; TTP relapse alone at 90 days was reduced from 62% to 0% (95% CI 0.36 to 0.88, P = 0.0002) with Pathway care. The number needed to treat to prevent TTP-RRD was 1.59 at 90 days. Over the project duration usual care demonstrated a hazard ratio for TTP-RRD of 12.58 compared to Pathway care. With the intervention, the duration of TPE was increased (median 6 vs 12 sessions, P < 0.05), as was use of rituximab (31.3% vs 93.8%, 95% CI −0.36 to −0.88, P = 0.003), and caplacizumab (6.3% vs 62.5%, 95% CI −0.027 to −0.81, P = 0.001). All Pathway patients underwent biochemical surveillance, and 31% had pre-emptive rituximab to reduce possibility of clinical relapse. A structured TTP Pathway significantly reduces morbidity and aligns care with modern clinical guidelines. The TMA Team is a valuable institutional resource to improve outcomes.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Purpura, Thrombotic ThrombocytopenicPatient Care TeamThrombotic MicroangiopathiesHumansFemaleMaleMiddle AgedPlasma ExchangeAdultTreatment OutcomeRituximabRetrospective StudiesProspective StudiesSingle-Domain AntibodiesAgedRecurrenceQuality Improvement

Substanzen

RituximabcaplacizumabSingle-Domain Antibodies

Autor:innen und Institutionen

  • Department of Medicine, West Virginia University School of Medicine, Morgantown, West Virginia, United States of America.
  • Department of Oncology, West Virginia University School of Medicine, Morgantown, United States of America.
  • Section of Nephrology, Department of Medicine, West Virginia University School of Medicine, Morgantown, United States of America.
  • Department of Pharmacy, West Virginia University School of Medicine, Morgantown, West Virginia, United States of America.
  • Department of Internal Medicine, Division of Medical Oncology, University of Kentucky, Lexington, Kentucky, United States of America.
  • Department of Pathology and Laboratory Medicine, University of Kentucky, Lexington, Kentucky, United States of America.

ORCID-Profile: Samuel A Merrill, Aaron D Shmookler

Zitieren

APA

Merrill, S. A., Yu, S., Webber, S. E., Gotses, J., Platt, E. L., Arays, R., & Shmookler, A. D. (2025). The TMA team and TTP pathway improved outcomes in a cohort with Thrombotic thrombocytopenic purpura. PLOS One. https://doi.org/10.1371/journal.pone.0325417

Vancouver

Merrill SA, Yu S, Webber SE, Gotses J, Platt EL, Arays R, et al. The TMA team and TTP pathway improved outcomes in a cohort with Thrombotic thrombocytopenic purpura. PLOS One. 2025. doi:10.1371/journal.pone.0325417

BibTeX
@article{Merrill2025,
  author = {Merrill, Samuel A and Yu, Stephen and Webber, Sylvia E and Gotses, John and Platt, Emma L and Arays, Ruta and Shmookler, Aaron D},
  title = {The TMA team and TTP pathway improved outcomes in a cohort with Thrombotic thrombocytopenic purpura},
  journal = {PLOS One},
  year = {2025},
  doi = {10.1371/journal.pone.0325417}
}
Kostenlos starten →